408508-52-1

Basic information

• Product Name: 2-Phenyl-7-aMinoquinoline
• Synonyms: 2-Phenyl-7-aMinoquinoline;2-Phenylquinolin-7-aMine
• CAS NO: 408508-52-1
• Molecular Formula: C₁₅H₁₂N₂
• Molecular Weight: 220.26918
• Mol File: 408508-52-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Phenyl-7-aMinoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenyl-7-aMinoquinoline(408508-52-1)
• EPA Substance Registry System: 2-Phenyl-7-aMinoquinoline(408508-52-1)

Safety Data

• Hazardous Substances Data: 408508-52-1(Hazardous Substances Data)

Usage

Description

2-Phenyl-7-aminoquinoline, an organic compound with the molecular formula C15H12N2, is a derivative of quinoline featuring a phenyl group at the 2-position and an amino group at the 7-position. Its unique structure positions it as a valuable building block in medicinal chemistry and pharmaceutical research for the synthesis of biologically active molecules.

Uses

Used in Medicinal Chemistry and Pharmaceutical Research:
2-Phenyl-7-aminoquinoline is utilized as a key building block for the synthesis of various biologically active molecules, contributing to the development of new drugs and therapeutic agents.
Used in Antimicrobial Applications:
It has been studied for its potential antimicrobial properties, making it a candidate for the development of new antimicrobial agents to combat resistant infections.
Used in Antiparasitic Applications:
2-Phenyl-7-aminoquinoline is also being investigated for its antiparasitic properties, which could lead to the creation of novel treatments for parasitic diseases.
Used in Antimalarial Applications:
2-Phenyl-7-aMinoquinoline has shown promise in antimalarial studies, indicating its potential use in developing new antimalarial drugs to address the growing issue of drug-resistant malaria.

Upstream product

• 87741-95-5 7-hydroxy-2-phenylquinoline 
• 7647-01-0 hydrogenchloride 
• 83352-96-9 2,4-Dinitrochalcone 
• 64-19-7 acetic acid 
• 98-86-2 acetophenone 
• 5551-12-2 4-bromo-2-nitrobenzaldehyde 
• 1203578-65-7 7-bromo-2-phenylquinoline 
• 1226-34-2 7-hydroxy-2-phenylquinoline-4-carboxylic acid 
• 855165-04-7 7-amino-2-phenyl-quinoline-4-carboxylic acid 

Downstream Products

• 857626-77-8 2,8-diphenyl-[1,7]phenanthroline-10-carboxylic acid 

Relevant articles and documents

In vitro and in vivo studies of the trypanocidal effect of novel quinolines

Therapies for human African trypanosomiasis and Chagas disease, caused by Trypanosoma brucei and Trypanosoma cruzi, respectively, are limited, providing minimal therapeutic options for the millions of individuals living in very poor communities. Here the effects of 10 novel quinolines are evaluated in silico and by phenotypic studies using in vitro and in vivo models. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties revealed that most molecules did not infringe on Lipinski’s rules, which is a prediction of good oral absorption. These quinolines showed high probabilities of Caco2 permeability and human intestinal absorption and low probabilities of mutagenicity and of hERG1 inhibition. In vitro screens against bloodstream forms of T. cruzi demonstrated that all quinolines were more active than the reference drug (benznidazole [Bz]), except for DB2171 and DB2192, with five (DB2187, DB2131, DB2186, DB2191, and DB2217) displaying 50% effective concentrations (EC50s) of 50s ranging from 0.6 to 0.1 M. All quinolines were also highly active in vitro against African trypanosomes, showing EC50s of ≤0.25 μM. The most potent and highly selective candidates for each parasite species were tested in in vivo models. Results for DB2186 were promising in mice with T. cruzi and T. brucei infections, reaching a 70% reduction of the parasitemia load for T. cruzi, and it cured 2 out of 4 mice infected with T. brucei. DB2217 was also active in vivo and cured all 4 mice (100% cure rate) with T. brucei infection.